GMAB / GENMAB / Likely this is the scenarioThe last 10 Years give us an idea how this stock moves.
Today i bough some expecting around 20% profit until End of July.
I look at Seasonality / seasonal price tendencies and identified a good period to be long in that stock. I have confidence in that and my entry was the break of yesterday candle.
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
1.77 USD
1.14 B USD
3.12 B USD
614.73 M
About GENMAB A/S
Sector
Industry
CEO
Jan G. J. van de Winkel
Website
Headquarters
Copenhagen
Founded
1998
FIGI
BBG004MPKM64
Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline includes daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma, teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease, and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel on June 11, 1998, and is headquartered in Copenhagen, Denmark.
See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Curated watchlists where GMAB is featured.